ATyr Pharma

aTyr Pharma and Foundation for Sarcoidosis Research Announce Town Hall Virtual Meeting on Sarcoidosis and Transitioning from Steroids to New and Investigational Therapies

Retrieved on: 
星期一, 三月 20, 2023
Sarcoidosis, Investigational New Drug, DSM-IV codes, Small RNA, ATyr Pharma, Quality of life, Scar, Prognosis, Granuloma, Fibrosis, Patient, FSR, SAN, Host, Chairperson, Death, Town hall, Pharmaceutical industry, Steroid

The event will be held on Saturday, March 25, 2023, at 12:00pm ET / 11:00am CT / 9:00am PT.

Key Points: 
  • The event will be held on Saturday, March 25, 2023, at 12:00pm ET / 11:00am CT / 9:00am PT.
  • The Town Hall discussion will feature a panel of leading experts related to sarcoidosis treatment and advocacy, including:
    John Carlin (Moderator) – Host, Sarc Fighter Podcast and Co-Chair, FSR Patient Advisory Committee
    Shambhu Aryal, M.D.
  • – Medical Director, Inova Lung Transplant Program and Inova Sarcoidosis Center, Inova Fairfax Hospital
    Registration is open to anyone who wishes to attend.
  • “We look forward to this discussion to help educate patients on evaluating sarcoidosis treatments and considerations for transitioning to a new therapy.

aTyr Pharma Announces Fourth Quarter and Full Year 2022 Results and Provides Corporate Update

Retrieved on: 
星期四, 三月 9, 2023
Transforming growth factor beta, EST, Medicine, IND, ATyr Pharma, Kyorin, European Medicines Agency, Conference, Clinical trial, Sarcoidosis, ILD, DC, Diagnosis, Interest, Food and Drug Administration, Systemic scleroderma, SAN, Committee, D, EMA, Fibrosis, Patient, FDA, Research, PST, Investigational New Drug, European Patent Office, Disease, American Thoracic Society, Food, Small RNA, European Patent Convention, Patent, Civil service commission, ATS, European Commission, Exercise, Investment, DARS, Scleroderma, Tokyo International Conference on African Development, Safety, Pharmaceutical industry, LTBP1, EU

SAN DIEGO, March 09, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (“aTyr” or the “Company”), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced fourth quarter and full year 2022 results and provided a corporate update.

Key Points: 
  • SAN DIEGO, March 09, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (“aTyr” or the “Company”), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced fourth quarter and full year 2022 results and provided a corporate update.
  • This achievement triggered a $10.0 million milestone payment to aTyr in the fourth quarter.
  • Based on the Company’s current operational plans and existing cash, aTyr believes the Company’s cash runway will extend into 2026.
  • Links to a live audio webcast and replay may be accessed on the aTyr website Events page at: http://investors.atyrpharma.com/events-and-webcasts .

aTyr Pharma to Present at March Investor Conferences

Retrieved on: 
星期三, 三月 8, 2023
Webcast, Corporation, Small RNA, Research, ATyr Pharma, Biology, Financial adviser, Vaccine, Pharmaceutical industry

In addition to the presentations, company management will be available to participate in one-on-one meetings with investors who are registered attendees of the conferences.

Key Points: 
  • In addition to the presentations, company management will be available to participate in one-on-one meetings with investors who are registered attendees of the conferences.
  • A webcast and replay of the Corporate Presentation will be available on the Investor’s section of the company’s website at www.atyrpharma.com .
  • aTyr is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform.
  • aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets.

aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2022 Financial Results

Retrieved on: 
星期四, 三月 2, 2023
ATyr Pharma, SAN, Small RNA, PIN, Conference, Biology, Telephone, Research, Pharmaceutical industry

Management will host a conference call and webcast to review the results and provide an operational update.

Key Points: 
  • Management will host a conference call and webcast to review the results and provide an operational update.
  • Participants may join the live webcast by accessing it at the above webcast registration link on the aTyr Events page.
  • aTyr is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase biology platform.
  • aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets.

aTyr Pharma Announces Phase 2 Study of Efzofitimod in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) Following FDA Clearance of IND Application

Retrieved on: 
星期三, 三月 1, 2023
Death, Neuropilin, Small RNA, Autoimmune disease, Safety, Skin, News, Quality of life, Scleroderma, Inflammation, Sarcoidosis, Cleveland Clinic, ATyr Pharma, Fibrosis, Fast Track, NRP2, Disease, Investigational New Drug, IND, Cell, Standard of care, FDA, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Toxicity, Trial of the century, Systemic scleroderma, SAN, Idiopathic pulmonary fibrosis, Cleveland, Pathology, U.S. FDA, Scar, Food, Lung, Pharmaceutical industry, Medical imaging, ILD

SAN DIEGO, March 01, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today provided additional details regarding its plans to initiate a Phase 2 study of its lead therapeutic candidate, efzofitimod, in patients with systemic sclerosis (SSc, also known as scleroderma)-associated interstitial lung disease (ILD) following the clearance of an Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) announced earlier this year.

Key Points: 
  • Efzofitimod has been granted U.S. FDA orphan drug designation for SSc and Fast Track designation for SSc-ILD.
  • Efzofitimod is a potential first-in-class immunomodulator that downregulates innate and adaptive immune responses in uncontrolled inflammatory disease states via selective modulation of neuropilin-2 (NRP2).
  • The company is currently investigating efzofitimod in patients with pulmonary sarcoidosis, a major form of ILD, in a global Phase 3 study called EFZO-FIT™.
  • Current treatment options may help to slow lung function decline but do not impact underlying disease or improve quality of life.

Bright Minds Biosciences Announces Non-Executive Director Appointment

Retrieved on: 
星期五, 二月 17, 2023
CMO, Elefsina, Biomedical sciences, Therapy, Michael J. Lenardo, SUNY, Rare, Proteostasis, NIH, Pain, Consultant, University, Neurology, Audit committee, Neuropharmacology, ATyr Pharma, Interim, CNS, Compensated emancipation, Weill Cornell Medicine, Jacobs School of Medicine and Biomedical Sciences, NOT, DSM-IV codes, FOR, School, Option, Epilepsy, The Michael J. Fox Foundation, Acadia Pharmaceuticals, CSE, Pimavanserin, MD, Pharmaceutical industry, Weill Cornell Medical Center, Buffalo

VANCOUVER, British Columbia, Feb. 17, 2023 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) (“Bright Minds” or the “Company”), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced the appointment to its board of directors (the “Board”) of David Weiner, MD, as a non-executive director. The appointment is effective immediately.

Key Points: 
  • “I am delighted to welcome David to the Bright Minds Board.
  • David holds several patents in the area of selective serotonin modulators, and we look forward to his contributions to the Company,” said Ian McDonald, CEO and Co-founder of Bright Minds Biosciences.
  • “It is an honor to join the Bright Minds Board as the Company transitions from a discovery to a development organization.
  • I am eager to share my perspectives and experience to help Bright Minds progress its innovative clinical and preclinical drug discovery programs,” stated David Weiner, MD.

aTyr Pharma Announces Pricing of Public Offering of Common Stock

Retrieved on: 
星期四, 二月 9, 2023
3rd Floor, Telephone, Scleroderma, Food, RNA transfection, Attention, ATyr Pharma, IND, Security (finance), RBC Capital Markets, Systemic scleroderma, S-3, Sale, Patient, SAN, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Equity capital markets, Form, Investigational New Drug, Park Avenue, Prospectus, Vesey Street

SAN DIEGO, Feb. 09, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced the pricing of its previously announced underwritten public offering of 22,225,000 shares of its common stock at a public offering price of $2.25 per share.

Key Points: 
  • SAN DIEGO, Feb. 09, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced the pricing of its previously announced underwritten public offering of 22,225,000 shares of its common stock at a public offering price of $2.25 per share.
  • The gross proceeds to aTyr from the offering, before deducting the underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $50.0 million.
  • In addition, aTyr has granted the underwriters a 30-day option to purchase up to an additional 3,333,750 shares of its common stock at the public offering price per share, less underwriting discounts and commissions.
  • All of the shares being sold in the offering are being sold by aTyr.

aTyr Pharma Announces Commencement of Public Offering of Common Stock

Retrieved on: 
星期三, 二月 8, 2023
3rd Floor, Telephone, Scleroderma, Food, RNA transfection, Attention, ATyr Pharma, IND, Security (finance), RBC Capital Markets, Systemic scleroderma, S-3, Sale, Patient, SAN, Capital market, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Equity capital markets, RBC, Biology, Form, Investigational New Drug, Park Avenue, Prospectus, Vesey Street, Research

In addition, aTyr expects to grant the underwriters a 30-day option to purchase additional shares of its common stock in an amount up to an additional 15% of the shares sold in the public offering.

Key Points: 
  • In addition, aTyr expects to grant the underwriters a 30-day option to purchase additional shares of its common stock in an amount up to an additional 15% of the shares sold in the public offering.
  • All of the shares to be sold in the offering are to be sold by aTyr.
  • The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.
  • These forward-looking statements include statements regarding the timing, terms and completion of the proposed public offering and anticipated use of proceeds from the offering.

aTyr Pharma Announces Achievement of Development Milestone by Partner Kyorin Pharmaceutical, Co., Ltd.

Retrieved on: 
星期一, 二月 6, 2023
Disease, Food, Food and Drug Administration, Safety, RNA transfection, ATyr Pharma, Inflammation, Neuropilin, NRP2, ILD, Interstitial lung disease, Sarcoidosis, E.U, Patient, SAN, FDA, Fast track (FDA), Medicine, Pharmaceutical industry, Kyorin

SAN DIEGO, Feb. 06, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (aTyr or the Company), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that its partner Kyorin Pharmaceutical Co., Ltd. (Kyorin), a wholly owned subsidiary of Kyorin Holdings, Inc., has dosed the first patient in Japan in EFZO-FIT™, a global pivotal Phase 3 study to evaluate the efficacy and safety of the Company’s lead therapeutic candidate, efzofitimod, in patients with pulmonary sarcoidosis, a major form of interstitial lung disease (ILD). This achievement has triggered a $10 million milestone payment by Kyorin to aTyr pursuant to a collaboration and license agreement between the Company and Kyorin.

Key Points: 
  • This achievement has triggered a $10 million milestone payment by Kyorin to aTyr pursuant to a collaboration and license agreement between the Company and Kyorin.
  • Efzofitimod is a first-in-class immunomodulator that downregulates innate and adaptive immune responses in uncontrolled inflammatory diseases states via selective modulation of neuropilin-2 (NRP2).
  • Kyorin has the exclusive rights to develop and commercialize efzofitimod in Japan for all forms of ILD.
  • The study intends to enroll 264 subjects with pulmonary sarcoidosis at multiple centers in the United States, Europe and Japan.

aTyr Pharma to Present New Data on the Mechanism of Action of Efzofitimod at the American Thoracic Society 2023 International Conference

Retrieved on: 
星期二, 一月 31, 2023
American Thoracic Society, RNA transfection, ATyr Pharma, Sarcoidosis, MOA, Myelocyte, DC, Conference, ATS, Patient, SAN, International Conference on Information Systems Security and Privacy, 2021 Essex County Council election, Pharmaceutical industry

SAN DIEGO, Jan. 31, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the company will present data on the mechanism of action (MOA) and exposure-efficacy analysis for its lead therapeutic candidate, efzofitimod, in an oral symposia presentation and poster session, respectively, at the American Thoracic Society (ATS) 2023 International Conference, which is scheduled to take place May 19 – 24 in Washington, DC.

Key Points: 
  • “These abstracts highlight the important data we continue to generate for efzofitimod and our clinical program in pulmonary sarcoidosis, a major form of interstitial lung disease with high unmet medical need,” said Sanjay S. Shukla, M.D., M.S., President and CEO of aTyr.
  • Additionally, an exposure-efficacy analysis of efzofitimod provides further confirmatory evidence of clinical proof-of-concept from our previous study.”
    Preliminary details of the presentations appear below.
  • Additional information regarding the presentations will be released closer to the date of the ATS conference.
  • Title: Efzofitimod, a Novel Immunomodulator for Pulmonary Sarcoidosis, Modulates Patient Inflammatory Responses Through Myeloid Cells